- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Mesothelioma Diagnostic Test that Predicts Survival Now Available
Validation studies presented at the annual meeting of the American Association for Thoracic Surgery push availability of the DecisionDx-Mesothelioma molecular test through an early access program.
th
Castle Biosciences Inc. announced that data from two validation studies of its DecisionDx-Mesothelioma molecular test were presented at the American Association for Thoracic Surgery 94 Annual Meeting. According to the data, the test accurately predicted survival in metastatic pleural mesothelioma (MPM) patients based on the gene expression profile signature of their tumor combined with clinical characteristics.
The results were reviewed during an oral presentation by Dr. Assunta De Rienzo, Ph.D., co-Director of the Thoracic Surgery Laboratory in the Department of Surgery, Thoracic Division, Brigham and Women's Hospital. The test, which combines the results of a gene expression profile with lymph node status and histology subtypes, had previously been validated in a prospective, single-center study. Following licensing of the technology from Brigham and Women's Hospital, CAP-accredited and CLIA-certified laboratory protocols were developed and validated in formalin-fixed paraffin embedded (FFPE) tissue. These results were from a second clinical validation study, which was conducted using a prospectively-planned, multi-center cohort study in conjunction with the National Mesothelioma Virtual Tissue Bank.
Read the report here: http://yhoo.it/1hdEKgp
Source: Yahoo finance
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
